Senseonics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company
focused on the development and commercialization of Eversense®, a
long-term, implantable continuous glucose monitoring (CGM) system for
people with diabetes, today announced the company plans to participate
in the LEERINK Partners 6th Annual Global Healthcare
Conference in New York.
Senseonics’ management is scheduled to present Wednesday, February 15,
2017 at 1:00 p.m. EST. Interested parties can access the live audio
webcast by navigating to the “Events & Publications” section of the
“Investor Relations” tab at www.senseonics.com.
An archived presentation will also be available on the website.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics’ first generation continuous glucose monitoring (CGM)
system, Eversense®, includes a small sensor, smart transmitter and
mobile application. Based on fluorescence sensing technology, the sensor
is designed to be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile device.
After insertion, the sensor is designed to continually and accurately
measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170203005723/en/
Senseonics Holdings, Inc.
R. Don Elsey, 301-556-1602
Chief
Financial Officer
[email protected]
Source: Senseonics Holdings, Inc.